首页> 美国卫生研究院文献>The Journal of Experimental Medicine >Cell-cell interaction in graft rejection responses: induction of anti- allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen
【2h】

Cell-cell interaction in graft rejection responses: induction of anti- allo-class I H-2 tolerance is prevented by immune responses against allo-class II H-2 antigens coexpressed on tolerogen

机译:移植排斥反应中的细胞间相互作用:针对耐受原上共表达的异源II H-2抗原的免疫反应可防止诱导抗异源I H-2耐受

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The intravenous sensitization of C57BL/6 (B6) mice with class I H-2- disparate B6-C-H-2bm1 (bm1) spleen cells results in almost complete abrogation of anti-bm1 CD8+ helper (proliferative and interleukin 2- producing) T cell (Th) activities. Although an appreciable portion of CD8+ cytotoxic T lymphocyte (CTL) precursors themselves remained after this regimen, such a residual CTL activity was eliminated after the engrafting of bm1 grafts, and these grafts exhibited prolonged survival. In contrast, the intravenous sensitization with (bm1 x B6-C-H- 2bm12 [bm12])F1 cells instead of bm1 cells failed to induce the prolongation of bm1 graft survival as well as bm12 and (bm1 x bm12)F1 graft survival. In the (bm1 x bm12)F1-presensitized B6 mice before as well as after the engrafting of bm1 grafts, anti-bm1 CTL responses that were comparable to or slightly stronger than those observed in unpresensitized mice were induced in the absence of anti-bm1 Th activities. bm1 graft survival was also prolonged by intravenous presensitization with a mixture of bm1 and bm12 cells but not with a mixture of bm1 and (bm1 x bm12)F1 cells. The capacity of CD4+ T cells to reject bm12 grafts was eliminated by intravenous presensitization with antigen-presenting cell (APC)-depleted bm12 spleen cells. However, intravenous presensitization with APC-depleted (bm1 x bm12)F1 cells failed to induce the prolongation of bm1 graft survival under conditions in which appreciably prolonged bm12 graft survival was induced. More surprisingly, bm1 graft survival was not prolonged even when the (bm1 x bm12)F1 cell presensitization was performed in CD4+ T cell-depleted B6 mice. This contrasted with the fact that conventional class I-disparate grafts capable of activating self Ia-restricted CD4+ as well as allo-class I-reactive CD8+ Th exhibited prolonged survival in CD4+ T cell-depleted, class I-disparate cell-presensitized mice. These results indicate that: (a) intravenous presensitization with class I- and II-disparate cells fails to reduce anti-allo-class I rejection responses that would otherwise be eliminated using only class I-disparate cells; (b) such failure is generated according to the coexpression of both classes of alloantigens on a single cell as tolerogen; and (c) allo-class II antigens coexpressed on tolerogen function to activate CD4+ as well as non-CD4+ Th leading to the generation of anti-class I effector T cell responses.
机译:对C57BL / 6(B6)小鼠的I-1类H-2异种B6-CH-2bm1(bm1)脾细胞进行静脉内致敏作用可几乎完全消除抗bm1 CD8 +辅助细胞(增殖和白介素2产生)的T细胞(四)活动。尽管在此方案之后,CD8 +细胞毒性T淋巴细胞(CTL)前体本身仍有相当一部分,但在植入bm1移植物后消除了这种残留的CTL活性,并且这些移植物显示出延长的生存期。相反,用(bm1 x B6-C-H-2bm12 [bm12])F1细胞而不是bm1细胞进行静脉内致敏不能诱导bm1移植物存活以及bm12和(bm1 x bm12)F1移植物存活的延长。在(bm1 x bm12)F1致敏的B6小鼠在植入bm1移植之前和之后,在不存在抗bm1的情况下,诱导的抗bm1 CTL反应与未敏化的小鼠相当或稍强。活动。通过bm1和bm12细胞混合物的静脉内预敏化,但bm1和(bm1 x bm12)F1细胞的混合物的静脉内预敏化也可以延长bm1移植物的存活。通过用抗原呈递细胞(APC)耗尽的bm12脾细胞进行静脉预敏化,消除了CD4 + T细胞排斥bm12移植物的能力。然而,在APC耗尽的(bm1 x bm12)F1细胞进行静脉预敏化后,在诱导bm12移植物存活时间显着延长的条件下,无法诱导bm1移植物存活时间的延长。更令人惊讶的是,即使在耗尽CD4 + T细胞的B6小鼠中进行了(bm1 x bm12)F1细胞预敏化,bm1移植物的存活也不会延长。这与以下事实形成了对比:能够激活自我Ia限制性的CD4 +以及异源I-反应性CD8 + Th的常规I类完全不同的移植物在CD4 + T细胞耗竭的,I类完全不同的细胞预敏小鼠中表现出延长的生存期。这些结果表明:(a)用I级和II级完全不同的细胞进行静脉预敏化不能减少I级抗Ilo排斥反应,否则仅使用I级完全不同的细胞即可消除; (b)这种失败是根据两种同种异体抗原在单个细胞上作为致耐受原的共表达而产生的; (c)在耐受原功能上共表达的同种II类抗原具有激活CD4 +和非CD4 + Th的功能,从而导致产生抗I类效应物T细胞反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号